Itonis, Inc. announces planned update on 10,000 commercial spots
for Emesyl anti-nausea relief
LAGUNA HILLS, CA -- April 13, 2016 -- InvestorsHub NewsWire
-- Itonis, Inc. (OTC PINKSHEETS: ITNS) Itonis, Inc. is
pleased to announce that it will begin airing its planned Ten
Thousand (10,000) thirty (30) second commercial spots for its
Emesyl product upon delivery of its first batch of product from
National Homeopathic Labs.
A previously signed agreement to provide marketing and public
relations services for its Emesyl product calls for placing the
10,000 commercial spots in select regional areas on the most
popular cable television networks available. The networks available
to Itonis for airing selection choice include ESPN, CNN, Fox News,
Discovery Channel, SPIKE, AMC, TBS, Lifetime, A&E, Comedy
Central, TV Land, Nickelodeon, Travel Channel, ESPN2, USA, HLN,
BET, MTV, SyFy, CMT, TLC, TNT, and FX, etc., and have the ability
to air more frequently in any of these select networks.
The closing of Oasis Health Products forced us to put a hold on
this commercial launch until we could secure additional product,
and now our new relationship with National Homeopathic Labs allows
us to move forward as planned. Were extremely excited that our
Emesyl commercials will finally become a reality, said Steve
Pidliskey, Itonis Vice President.
About Itonis, Inc.
Located in Laguna Hills, California, and founded in 2005, Itonis
Inc. has focused on the distribution of innovative products to the
medical and pharmaceutical industries. The company also holds a
licensing agreement with MyECheck Inc, which allows the company to
use MyEChecks patented mobile payment application and share
transaction revenue fees for point of purchase payments across
various industries. Please visit www.itonisholdings.com for additional information.
About National Homeopathic Labs.
Located in Las Vegas, Nevada, the company is a cGMP, FDA
registered contract manufacturer that specializes in formula
development and packaging of homeopathic, nutritional, cosmeceutal,
and dietary supplements.
Safe Harbor:
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's affiliates that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, seasonal
changes, and other risks detailed from time to time in the
Company's filings with the U.S. Securities and Exchange Commission.
The actual results may differ materially from those contained in
this press release. The Company disclaims any obligation to update
any statements in this press release.
Contact:
Itonis, Inc.
Office@itonisholdings.com
